SS-31
Also known as Elamipretide, Forzinity
A small peptide that protects the mitochondria. Approved in the US for Barth syndrome, a rare inherited disease.
Quick facts
- Status
- Approved medicine in the US
- Evidence
- Approved in the US for a rare disease
- Taken as
- Injection under the skin
- Common sizes
- 10 mg, 30 mg, 50 mg
- Category
- Mitochondria-targeted peptide
How it works
It sticks to the inner wall of the mitochondria and helps them keep making energy normally.
What it’s used for
- Barth syndrome (approved in the US)
- "Anti-ageing" and energy (not approved)
What the research shows
- Approved in the US in 2025 based on trials in Barth syndrome.
- Trials in other diseases have had mixed results.
Side effects & risks
- Injection-site reactions were very common in trials
- Outside its approved use, benefits are unproven
Is it legal?
Approved in the US (FDA accelerated approval, September 2025) as Forzinity for Barth syndrome. Not approved in the EU or UK. Use for other purposes (e.g. anti-ageing) is off-label or unapproved.
Storage & safe handling
- Only use as prescribed and supervised by a doctor.
- Store exactly as described in the patient leaflet.
- Use a new sterile needle every time and dispose of it in a sharps container.
Open in PepTimerTrack your protocol, calculate how much to draw and get reminders — free.Open in PepTimer
Sources: FDA accelerated approval of elamipretide (Forzinity) for Barth syndrome, September 2025.
Last updated 12 October 2026. Information — not medical advice. PepTimer does not replace a doctor. Many peptides are not approved medicines in the EU, UK or US. Talk to a qualified healthcare provider before starting, changing or stopping any treatment.
Last updated 12 October 2026. Information — not medical advice. PepTimer does not replace a doctor. Many peptides are not approved medicines in the EU, UK or US. Talk to a qualified healthcare provider before starting, changing or stopping any treatment.